help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2007-0210
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCarthy, T. L.
Right arrow Articles by Centrella, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCarthy, T. L.
Right arrow Articles by Centrella, M.
Molecular Endocrinology 21 (11): 2713-2724
Copyright © 2007 by The Endocrine Society

Prostaglandin E2 Increases Transforming Growth Factor-ß Type III Receptor Expression through CCAAT Enhancer-Binding Protein {delta} in Osteoblasts

Thomas L. McCarthy, Tony H. Pham, Bianca I. Knoll and Michael Centrella

Department of Surgery and Section of Plastic Surgery, Yale University School of Medicine, New Haven, Connecticut 06520

Address all correspondence and requests for reprints to Thomas L. McCarthy or Michael Centrella, 333 Cedar Street, MS 208041, New Haven, Connecticut 06520-8041. E-mail: thomas.mccarthy{at}yale.edu or michael.centrella{at}yale.edu.

Variations in individual TGF-ß receptors (TßRs) may modify TGF-ß activity and significantly alter its effects on connective tissue growth or repair. Differences in the amount of TßR type III (TßRIII) relative to signal transducing TßRI occur on bone cells during differentiation or in response to other growth regulators. Here we investigated prostaglandin (PG) E2, a potent effector during trauma, inflammation, or mechanical load, on TßR expression in primary osteoblast-enriched cultures. PGE2 rapidly increased TßRIII mRNA and protein expression and enhanced TßRIII gene promoter activity through a discrete region within 0.4 kb of the transcription start site. PGE2 alters osteoblast function through multiple signal-inducing pathways. In this regard, protein kinase A (PKA) activators, PGE1 and forskolin, also enhanced gene expression through the TßRIII gene promoter, whereas protein kinase C activators, PGF2{alpha} and phorbol myristate acetate, did not. The stimulatory effect of PGE2 on TßRIII promoter activity was suppressed by a dominant negative PKA-regulatory subunit, but not by dominant negative protein kinase C. PGE2 specifically increased nuclear factor CCAAT enhancer-binding protein {delta} (C/EBP{delta}) binding to a half-binding site upstream of the basal TßRIII promoter region, and promoter activity was sensitive to C/EBP{delta} overexpression and to dominant-negative C/EBP{delta} competition. In parallel with their effect on TßRIII expression, activators of PKA decreased TGF-ß-induced activity. In summary, high levels of PGE2 that occur with inflammation or trauma may, through PKA-activated C/EBP{delta}, preferentially increase TßRIII expression and in this way delay TGF-ß-dependent activation of osteoblasts during the early stabilization phase of bone repair.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society